The Biotechnology Industry Organization and Generic Pharmaceutical Association are jointly raising concerns about aspects of a recently introduced House compounding bill that is the subject of bicameral talks, including the measure's volume limit and other sections they say could still allow large-scale copying of FDA-approved drugs.
No comments:
Post a Comment